IL13 and asthma: However, in later phase 3 randomized control trials, LAVOLTA I and LAVOLTA II, the anti-IL13 monoclonal antibody lebrikizumab, reduced asthma exacerbations in periostin-high subjects, but the effect reached statistical significance only in the former study, despite the inhibition of IL13 axis in both, which likely points to the complexity of cell–matrix interactions and loopholes through which inflammation and fibrosis ultimately develop [15].